Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

NCT03904108 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped insufficient patient population to complete trial as planned

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Ramucirumab

Sponsor

ROGER S KERESZTES MD